FORA Capital LLC Sells 6,967 Shares of Charles River Laboratories International, Inc. $CRL

Key Points

• FORA Capital LLC reduced its stake in Charles River Laboratories by 76.9% in the first quarter, owning only 2,093 shares after selling 6,967.
• Charles River Laboratories reported $3.12 EPS for the last quarter, exceeding analyst expectations, along with a revenue of $1.03 billion.
• Wall Street analysts have a consensus rating of "Hold" for Charles River Laboratories, with an average price target of $175.69.

FORA Capital LLC reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 76.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 2,093 shares of the medical research company's stock after selling 6,967 shares during the period. FORA Capital LLC's holdings in Charles River Laboratories International were worth $315,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CRL. Kovitz Investment Group Partners LLC acquired a new stake in Charles River Laboratories International during the 4th quarter worth approximately $217,000. The Manufacturers Life Insurance Company raised its holdings in shares of Charles River Laboratories International by 41.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 194,677 shares of the medical research company's stock valued at $35,937,000 after purchasing an additional 57,412 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Charles River Laboratories International by 13.5% in the fourth quarter. Northern Trust Corp now owns 492,218 shares of the medical research company's stock valued at $90,863,000 after purchasing an additional 58,398 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in shares of Charles River Laboratories International by 4.0% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 3,963 shares of the medical research company's stock valued at $732,000 after purchasing an additional 152 shares during the last quarter. Finally, Wahed Invest LLC raised its holdings in shares of Charles River Laboratories International by 6.5% in the fourth quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after purchasing an additional 81 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock traded up $0.07 during trading on Friday, reaching $163.29. The company's stock had a trading volume of 860,239 shares, compared to its average volume of 956,203. The business's 50-day moving average price is $159.32 and its 200-day moving average price is $148.75. The firm has a market cap of $8.04 billion, a PE ratio of -122.77, a P/E/G ratio of 5.22 and a beta of 1.47. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $230.02. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International's revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.80 earnings per share. Equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 17th. Barclays lifted their price objective on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the company an "equal weight" rating in a report on Thursday, August 7th. Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their target price for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. Finally, Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their target price for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. Five investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $175.69.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the transaction, the executive vice president owned 24,116 shares of the company's stock, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).